Stock Ratings / Health Care / TTRX / dividends

PRLD (41) ENTA (25) ARCT (31) AVIR (40) ⌘ Pro Terminal →

Turn Therapeutics Inc. (TTRX) Dividend Safety Gauge & 10-Year DRIP Compounder

$10.72 -3.60% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.63

Turn Therapeutics Inc. (TTRX) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $327.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $10.63 (-0.84%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-12.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TTRX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (31/100 Composite)

🔍 WHY TTRX SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (32% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (26% of score)

FRED Regime × Technicals: 59% of 52W Range • RSI-14 at 43.4 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$12.00-11.9% Next Q

Q2 (-2Q)

Grade E$10.57-2.7% Next Q

Q3 (-1Q)

Grade E$10.28+4.3% Next Q

Current

Grade E$10.72-9.4% Hist 90D α

Trajectory: E (39) → E (31)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a TTRX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While TTRX currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.72) and Max Pain ($11.26) forces dealer call-delta covering toward $17.27.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TTRX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “TTRX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 31%NO 69%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TTRX)

✓Walkthrough of TTRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

TTRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +190.51%▼ SUPPORT BREAKDOWN

2026-10-30O $10.45H $10.72L $9.60C $10.72VOL 137.1K

RES: $20.71SUP: $12.02SMA50: $11.72SMA200: $7.00

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TTRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TTRX Butterfly Map → + Track TTRX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on TTRX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TTRX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for TTRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TTRX)

Health Care Rank #919 of 1016 ⚔️ PRLD vs TTRX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TTRX vs. PRLD, ENTA, ARCT, AVIR)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Turn Therapeutics Inc. (TTRX) ranks #919 by composite RQD confidence (31/100, grade E) and #511 by equity capitalization ($327.3M). Within this direct 5-issuer industry benchmark cohort, TTRX leads on earnings valuation at N/A trailing P/E, while TTRX leads on capital efficiency and profitability with -28.3% ROIC and — gross margin. PRLD currently holds the highest overall quantitative score in the immediate peer group at 41/100 (D-) compared with TTRX at 31/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
TTRX ACTIVE Turn Therapeutics Inc.	E	31/100	—	—	-28.3%	-3.60%	$327.3M	Benchmark Subject
PRLD Prelude Therapeutics Incorporated	D-	41/100	—	—	-35.0%	-0.97%	$327.2M	/prld-vs-ttrx →
ENTA Enanta Pharmaceuticals Inc.	E	25/100	—	—	-35.0%	-3.46%	$324.7M	/enta-vs-ttrx →
ARCT Arcturus Therapeutics Holdings Inc.	E	31/100	—	—	-35.0%	+0.66%	$345.3M	/arct-vs-ttrx →
AVIR Atea Pharmaceuticals Inc.	D-	40/100	—	—	-35.0%	+0.94%	$345.7M	/avir-vs-ttrx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002023016

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Turn Therapeutics Inc. (TTRX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$3.2M, operating cash flow of -$2.6M, and free cash flow of -$2.6M (-88.3% YoY). On the balance sheet, TTRX closed FY2025 with $12.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$3.2M	-$2.6M	-$2.6M	$12.2M	—
FY2024 (FY)	2024-12-31	$0	-$1.8M	-$1.4M	-$1.4M	$2.0M	—

3. TTRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TTRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Turn Therapeutics Inc. (NASDAQ: TTRX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $10.72 (-3.60% 1D, market cap $327.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, TTRX ranks #919 in composite RQD confidence.

How does TTRX compare to PRLD and ENTA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TTRX carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -28.3%. By comparison, PRLD (Prelude Therapeutics Incorporated) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $327.2M) and ENTA (Enanta Pharmaceuticals Inc.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $324.7M). Among the 5-stock peer group, TTRX leads on earnings multiple (N/A) while TTRX leads on capital efficiency (-28.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TTRX?

Per TTRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002023016), Turn Therapeutics Inc. generated $0 in revenue, -$3.2M in net income, and -$2.6M in free cash flow against $12.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TTRX trading relative to its 50-day, 200-day, and 52-week technical levels?

TTRX last traded at $10.72 (-3.60% on volume of 137,714 shares), positioning the stock -8.53% below its 50-day simple moving average ($11.72) and +53.14% above its 200-day simple moving average ($7.00). Across its 52-week range of $2.57 to $16.45, TTRX sits at the 58.7% percentile with a 14-day RSI of 43.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($9.38 to $12.06).

TTRX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does TTRX pay a dividend and is it safe?

Turn Therapeutics Inc. (TTRX) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: TTRX RQD Cockpit TTRX 12M Forecast TTRX Earnings & Move TTRX Dividends & DRIP TTRX Insiders & 13F TTRX Whale Options TTRX Profit Sankey TTRX News & Why